Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-05-02
2000-02-15
Mach, D Margaret
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514312, 514418, 514419, 514424, 514289, A61K 31405, A61K 3140, A61K 3145, A61K 3144
Patent
active
06025369&
ABSTRACT:
The present invention relates to the novel finding that homocysteine affects the initiation and/or progress of atherosclerosis via a receptor-mediated growth factor effect on vascular smooth muscle cells. This growth factor effect can be inhibited by N-methyl-D-aspartate antagonists via a unique receptor that is in the NMDA receptor family. Through the use of cloning and other procedures, this homocysteine receptor can be characterized in order to develop novel pharmacologic strategies that the address the receptor for the prevention and treatment of atherosclerosis.
REFERENCES:
patent: 5248671 (1993-09-01), Smith
patent: 5334618 (1994-08-01), Lipton
Albers, G., et al., "Tolerability of Oral Dextromethorphan in Patients with a History of Brain Ischemia", Clin. Neuropharmacology, 15(6):509-514 (1992).
Bigge, C., "Structural Requirements for the Development of Potent N-Methyl-D-Aspartic Acid (NMDA) Receptor Antagonists", Biochem. Pharm., 45(8):1547-1561 (1993).
Boers, G., "Heterozygosity for Homocystinuria in Premature Peripheral and Cerebral Occlusive Arterial Disease", The New England J. of Medicine, 313(12) 709-715 (1985).
Brattstrom, L., "Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors", European J. Clin. Invest., 22(3):214-221 (1992).
Clarke, R., "Hyperhomocysteinemia: An Independent Risk Factor for Vascular Disease" The New England J. of Medicine, 324(17):1149-1155 (1991).
Faden, A., "Pharamacological Strategies in CNS Trauma", TiPS, 13:29-35 (1992).
Jane, D.E., "Agonists and Competitive Antagonists: Structure-Activity and Molecular Modelling Studies", Agonists and Competitive Antagonists, Chapter 2, pp. 31-104.
Kim, W., "Involvement of N-Methyl-D-Aspartate Receptor and Free Radical in Homocysteine-Mediated Toxicity on Rat Cerebellar Granule Cells in Culture", Neuroscience Letters 216:117-120 (1996).
Li, J.,. "Potent, Orally Active, Competitive N-Methyl-D-Aspartate (NMDA) Receptor Antagonists Are Substrates for a Neutral Amino Acid Uptake System in Chinese Hamster Ovary Cells", J. Med. Chem. 38(11):1955-1965 (1995).
Meldrum, B., "Excitatory Amino Acid Neurotoxicity and Neurodegenerative Disease", TiPS 11:380-387 (1990).
Patneau, D., "Structure-Activity Relationships for Amino Acid Transmitter Candidates Acting at N-Methyl-D-Aspartate and Quisqualate Receptors", The J. of Neuroscience 10(7):2385-2399 (1990).
Raines, E., "Smooth Muscle Cells and the Pathogenesis of the Lesions of Atherosclerosis", Br Heart, 69 (Supplement): S30-S37 (1993).
Rogawski, M., "Therapeutic Potential of Excitatory Amino Acid Antagonists: Channel Blockers and 2,3-benzodiazepines", TiPS, 14:325-331 (1993).
Rosenquist, T., "Homocysteine Induces Congenital Defects of the Heart and Neural Tube: Effect of Folic Acid", Proc. Natl. Acad. Sci. USA, 93:15227-15232 (1996).
Ross, R., "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s ", Nature, 362(6423):801-809 (1993).
Selhub, J., "Association Between Plasma Homocysteine Concentrations and Extracranial Carotid-Artery Stenosis", The New England J. of Medicine, 332(5):286-291 (1995).
Simons, M., "Antisense c-myb Oligonucleotides Inhibit Intimal Arterial Smooth Muscle Cell Accumulation in vivo", Nature, 359:67-70 (1992).
Steinberg, G., "Dextromethorphane Alters Cerebral Blood Flow and Protects Against Cerebral Injury Following Focal Ischemia", NSL08233, 225-228 (1991).
Suckling, K., "Emerging Strategies for the Treatment of Atherosclerosis as Seen From the Patent Literature", Biochemical Society Transactions 646th Meeting Leeds, 21(3):660-662 (1993).
Suckling, K., "Atherosclerosis Patents: Clues to the Next Drug Generation", Bio/Technology, 12:1379-1380 (1994).
Tsai, J., "Promotioin of Vascular Smooth Musle Cell Growth by Homocysteine: A Link to Atherosclerosis", Proc. Natl. Acad. Sci. USA 81:6369-6373 (1994).
Watkins, J., "Structure-Activity Relationships in the Development of Excitatory Amino Acid Receptor Agonists and Competitive Antagonists", TiPS Special Report, 4-12 (1991).
Willetts, J., "The Behavioral Pharmacology of NMDA Receptor Antagonists", TiPS 11:423-428 (1990).
Wolfe, T., "Massive Dextromethorphan Ingestion and Abuse", Am. J. of Emergency Med., 13(2):174-176 (1995).
"The Homocysteine Saga: B6, B12, and Folate", Medical Scienses Bulletin, Apr. 1994.
KIM, "S-Nitrosation Ameliorates Homocysteine-Mediated Neurotoxicity in Primary Culture Rat Cortical Neurons", Korean Society of Pharmacology, Taehan Yakrihak Chapchi, (1996), 32(2), 169-175; ABSTRACT NO. 126:73089, abstract only.
Andaloro Vincent J.
Gadson Preston F.
Monaghan Daniel T.
Rosenquist Thomas H.
Mach D Margaret
The Board of Regents of the University Nebraska
LandOfFree
N-methyl-D-aspartate (NMDA) receptor blockers for the prevention does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-methyl-D-aspartate (NMDA) receptor blockers for the prevention, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-methyl-D-aspartate (NMDA) receptor blockers for the prevention will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1906182